MCID: CRB088
MIFTS: 43

Cerebral Atrophy malady

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Atrophy

Aliases & Descriptions for Cerebral Atrophy:

Name: Cerebral Atrophy 51 29 69

Classifications:



Summaries for Cerebral Atrophy

NINDS : 51 Cerebral atrophy is a common feature of many of the diseases that affect the brain. Atrophy of any tissue means loss of cells. In brain tissue, atrophy describes a loss of neurons and the connections between them. Atrophy can be generalized, which means that all of the brain has shrunk; or it can be focal, affecting only a limited area of the brain and resulting in a decrease of the functions that area of the brain controls. If the cerebral hemispheres (the two lobes of the brain that form the cerebrum) are affected, conscious thought and voluntary processes may be impaired.

MalaCards based summary : Cerebral Atrophy is related to keratosis follicularis, dwarfism, and cerebral atrophy and autosomal recessive cerebral atrophy, and has symptoms including headache An important gene associated with Cerebral Atrophy is VPS53 (VPS53, GARP Complex Subunit), and among its related pathways/superpathways is Lysosome. The drugs Acetylcholine and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and testes, and related phenotype is Increased viability with MLN4924 (a NAE inhibitor).

Wikipedia : 71 Cerebral atrophy is a common feature of many of the diseases that affect the brain.Atrophy of any tissue... more...

Related Diseases for Cerebral Atrophy

Diseases in the Cerebral Atrophy family:

Autosomal Recessive Cerebral Atrophy

Diseases related to Cerebral Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
id Related Disease Score Top Affiliating Genes
1 keratosis follicularis, dwarfism, and cerebral atrophy 11.9
2 autosomal recessive cerebral atrophy 11.8
3 pontocerebellar hypoplasia, type 2e 11.5
4 prieto syndrome 11.4
5 incontinentia pigmenti 11.0
6 epileptic encephalopathy, early infantile, 17 10.8
7 aicardi-goutieres syndrome 3 10.8
8 aicardi-goutieres syndrome 7 10.8
9 aicardi-goutieres syndrome 1, dominant and recessive 10.8
10 asparagine synthetase deficiency 10.8
11 pontocerebellar hypoplasia type 2a 10.8
12 pontocerebellar hypoplasia type 2d 10.8
13 prieto x-linked mental retardation syndrome 10.8
14 cerebritis 10.8
15 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.7
16 ceroid lipofuscinosis, neuronal, 7 10.7
17 galloway-mowat syndrome 10.7
18 ceroid lipofuscinosis, neuronal, 3 10.7
19 ceroid lipofuscinosis, neuronal, 8 10.7
20 ceroid lipofuscinosis, neuronal, 10 10.7
21 aicardi-goutieres syndrome 4 10.7
22 ceroid lipofuscinosis, neuronal, 2 10.7
23 ceroid lipofuscinosis, neuronal, 1 10.7
24 aicardi-goutieres syndrome 5 10.7
25 ceroid lipofuscinosis, neuronal, 4, parry type 10.7
26 aicardi-goutieres syndrome 6 10.7
27 aicardi-goutieres syndrome 10.7
28 neurodevelopmental disorder with hypotonia, seizures, and absent language 10.7
29 aicardi-goutieres syndrome 2 10.7
30 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.7
31 encephalopathy, familial, with neuroserpin inclusion bodies 10.7
32 ceroid lipofuscinosis, neuronal, 5 10.7
33 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.7
34 oculopalatocerebral syndrome 10.7
35 ceroid lipofuscinosis, neuronal, 6 10.7
36 dementia 10.2
37 hydrocephalus 10.1
38 mitochondrial myopathy with diabetes 10.0 CLN5 CLN6
39 deafness and myopia 10.0 CLN5 CLN6
40 microcephaly 9, primary, autosomal recessive 10.0 CLN5 CLN6
41 schizophrenia 10.0
42 myopia 10 10.0 CLN5 CLN6
43 wilms tumor 2 9.9 CLN5 CLN6
44 primary cutaneous amyloidosis 9.9 RNASEH2A RNASEH2B
45 brain injury 9.9
46 urinary schistosomiasis 9.9 CLN5 CLN6
47 normal pressure hydrocephalus 9.8
48 encephalopathy 9.8
49 anorexia nervosa 9.8
50 traumatic brain injury 9.8

Graphical network of the top 20 diseases related to Cerebral Atrophy:



Diseases related to Cerebral Atrophy

Symptoms & Phenotypes for Cerebral Atrophy

UMLS symptoms related to Cerebral Atrophy:


headache

GenomeRNAi Phenotypes related to Cerebral Atrophy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 8.8 RNASEH2A RNASEH2B VPS53

Drugs & Therapeutics for Cerebral Atrophy

Drugs for Cerebral Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4 51-84-3 187
2
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2 145258-61-3 6438354
3
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Galantamine Approved Phase 4,Phase 3 357-70-0 9651 908828, 9651
8
Memantine Approved, Investigational Phase 4 19982-08-2 4054
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
11
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 147245-92-9 3081884
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
14
Interferon beta-1b Approved Phase 4,Phase 2 145155-23-3
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
18
Choline Approved, Nutraceutical Phase 4 62-49-7 305
19 interferons Phase 4,Phase 3,Phase 2
20 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
21 Cholinergic Agents Phase 4,Phase 3,Phase 1
22 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
23 Neuromuscular Agents Phase 4
24 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 abobotulinumtoxinA Phase 4
32 Immunoglobulins Phase 4,Phase 2,Phase 3
33 incobotulinumtoxinA Phase 4
34 onabotulinumtoxinA Phase 4
35 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
36 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
37 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Interferon-beta Phase 4,Phase 3,Phase 2
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Antibodies Phase 4,Phase 2,Phase 3
43 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
44 Botulinum Toxins Phase 4
45 Botulinum Toxins, Type A Phase 4
46 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Prednisolone acetate Phase 4
48 Dexamethasone acetate Phase 4 1177-87-3
49 glucocorticoids Phase 4
50 Folic Acid Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 295)
id Name Status NCT ID Phase
1 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
2 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
3 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4
4 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4
5 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4
6 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
7 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4
8 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4
9 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4
10 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4
11 The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT01921972 Phase 4
12 Myobloc Atrophy Study Completed NCT02052024 Phase 4
13 Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy Completed NCT00377364 Phase 4
14 Effect of Fingolimod on Neurodegeneration Recruiting NCT02575365 Phase 4
15 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03046693 Phase 4
16 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Not yet recruiting NCT02462018 Phase 4
17 Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate Terminated NCT00203047 Phase 4
18 Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury Unknown status NCT01260090 Phase 3
19 Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis Unknown status NCT00545493 Phase 2, Phase 3
20 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3
21 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3
22 Magnetic Stimulation Therapy for Treating Vascular Depression Completed NCT00044798 Phase 3
23 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed NCT00236574 Phase 3
24 Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3
25 Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline Completed NCT00878631 Phase 2, Phase 3
26 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3
27 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
28 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3
29 Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease Completed NCT00951834 Phase 2, Phase 3
30 Omega-3 Fatty Acid Treatment in Multiple Sclerosis Completed NCT00360906 Phase 2, Phase 3
31 Study About Efficacy and Safety to Treat Multi-System-Atrophy Completed NCT00146809 Phase 3
32 Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome Completed NCT00666224 Phase 3
33 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3
34 Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis Completed NCT00622700 Phase 3
35 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3
36 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3
37 Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support Completed NCT00268944 Phase 3
38 Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Recruiting NCT02201108 Phase 3
39 National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Ph Recruiting NCT02937285 Phase 3
40 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Recruiting NCT01671384 Phase 3
41 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Recruiting NCT02071459 Phase 2, Phase 3
42 Resveratrol and Huntington Disease Recruiting NCT02336633 Phase 3
43 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) Active, not recruiting NCT00835770 Phase 3
44 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Active, not recruiting NCT01760005 Phase 2, Phase 3
45 The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Active, not recruiting NCT01767909 Phase 2, Phase 3
46 Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Not yet recruiting NCT03122652 Phase 3
47 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3
48 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3
49 Phase 3 IGIV, 10% in Alzheimer´s Disease Terminated NCT01524887 Phase 3
50 Study of Rifampicin in Multiple System Atrophy Terminated NCT01287221 Phase 3

Search NIH Clinical Center for Cerebral Atrophy

Genetic Tests for Cerebral Atrophy

Genetic tests related to Cerebral Atrophy:

id Genetic test Affiliating Genes
1 Cerebral Atrophy 29

Anatomical Context for Cerebral Atrophy

MalaCards organs/tissues related to Cerebral Atrophy:

39
Brain, Temporal Lobe, Testes, Pineal, Thyroid, Kidney, Liver

Publications for Cerebral Atrophy

Articles related to Cerebral Atrophy:

(show top 50) (show all 397)
id Title Authors Year
1
Cockayne syndrome with intracranial calcification, hypomyelination, and cerebral atrophy. ( 28149095 )
2017
2
On aA remarkable syndrome of cerebral atrophy associated with hyperammonaemia in childhood. ( 27577062 )
2016
3
Pontine and cerebral atrophy in Lennox-Gastaut syndrome. ( 26808205 )
2016
4
Reversible Cerebral Atrophy in Infantile Tremor Syndrome. ( 27395831 )
2016
5
Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysis. ( 27239527 )
2015
6
Retinal neurodegeneration on optical coherence tomography and cerebral atrophy. ( 25451722 )
2015
7
Cerebral atrophy is linked to clinical severity and worsens with aging in patients with Pelizaeus-Merzbacher disease and Spastic Paraplegia type 2. ( 26531569 )
2015
8
Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors. ( 25523616 )
2015
9
Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. ( 25990306 )
2015
10
Parry-Romberg syndrome associated with contralateral cerebral atrophy. ( 26771367 )
2015
11
Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. ( 26239178 )
2015
12
Long-Term Migration of a Deep Brain Stimulation (DBS) Lead in the Third Ventricle Caused by Cerebral Atrophy in a Patient with Anterior Thalamic Nucleus DBS. ( 26819942 )
2015
13
Progressive cerebral atrophy in neuromyelitis optica. ( 26359279 )
2015
14
Subdural hemorrhages associated with antithrombotic therapy in infants with cerebral atrophy. ( 25113301 )
2014
15
Retraction. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008 Dec;131(Pt 12):3311a8934. doi:10.1093/brain/awn288. ( 24860127 )
2014
16
Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy. ( 24045571 )
2014
17
Cerebral atrophy in a vitamin B12-deficient infant of a vegetarian mother. ( 25076673 )
2014
18
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy. ( 24515696 )
2014
19
An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. ( 25516199 )
2014
20
Association of SORL1 gene variants with hippocampal and cerebral atrophy and Alzheimer's disease. ( 24938503 )
2014
21
VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). ( 24577744 )
2014
22
Cerebral atrophy and subdural haemorrhage after cerebellar and cerebral infarcts in an 8-month-old child after having been stung by a scorpion. ( 24962491 )
2014
23
Evolution of a symptomatic diffuse developmental venous anomaly with progressive cerebral atrophy in an atypical case of Sturge-Weber syndrome. ( 25547041 )
2014
24
Cerebral atrophy and dementia in type 2 diabetes mellitus: report of two cases and review of literature. ( 24956625 )
2014
25
Methylglyoxal, cognitive function and cerebral atrophy in older people. ( 22496536 )
2013
26
Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: a positron emission tomography study corrected for cerebral atrophy. ( 24098376 )
2013
27
Cerebral atrophy is an independent risk factor for unfavorable outcome after spontaneous supratentorial intracerebral hemorrhage. ( 23412376 )
2013
28
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. ( 23303849 )
2013
29
Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome. ( 22890637 )
2013
30
Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage. ( 23662822 )
2013
31
Cerebral atrophy in elderly with subjective memory complaints. ( 23239111 )
2013
32
P-selectin Expression Tracks Cerebral Atrophy in Mexican-Americans. ( 22558002 )
2012
33
How much do focal infarcts distort white matter lesions and global cerebral atrophy measures?. ( 23154746 )
2012
34
Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments. ( 20970891 )
2012
35
Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. ( 21596458 )
2012
36
Cerebral atrophy is associated with development of chronic subdural haematoma. ( 22759238 )
2012
37
Age-associated cerebral atrophy in mouse lemur primates. ( 19564059 )
2011
38
I^-Amyloid (1-42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. ( 22187546 )
2011
39
Transplantation of marrow stromal cells restores cerebral blood flow and reduces cerebral atrophy in rats with traumatic brain injury: in vivo MRI study. ( 21275806 )
2011
40
Intracranial air correlates with preoperative cerebral atrophy and stereotactic error during bilateral STN DBS surgery for Parkinson's disease. ( 21778795 )
2011
41
Rapid progressive cerebral atrophy in systemic lupus erythematosus. ( 22134797 )
2011
42
Functional abnormalities and cerebral atrophy in posttraumatic stress disorder and dementia: is there a causal link between the two diseases? ( 21314666 )
2011
43
Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment. ( 20813341 )
2010
44
Marked cerebral atrophy is correlated with kidney dysfunction in nondisabled adults. ( 20944639 )
2010
45
Retinal microvascular signs and 10-year risk of cerebral atrophy: the Atherosclerosis Risk in Communities (ARIC) study. ( 20576949 )
2010
46
A patient with PHACE syndrome with marked ipsilateral cerebral atrophy. ( 20417465 )
2010
47
Cerebral atrophy in cerebrovascular disorders. ( 19344366 )
2010
48
Generalized cerebral atrophy seen on MRI in a naturally exposed animal model for Creutzfeldt-Jakob disease. ( 21108848 )
2010
49
Differential associations of cortical and subcortical cerebral atrophy with retinal vascular signs in patients with acute stroke. ( 20813998 )
2010
50
Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. ( 20299484 )
2010

Variations for Cerebral Atrophy

Expression for Cerebral Atrophy

Search GEO for disease gene expression data for Cerebral Atrophy.

Pathways for Cerebral Atrophy

Pathways related to Cerebral Atrophy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.71 CLN5 PPT1

GO Terms for Cerebral Atrophy

Cellular components related to Cerebral Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ribonuclease H2 complex GO:0032299 8.62 RNASEH2A RNASEH2B

Biological processes related to Cerebral Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 retrograde transport, endosome to Golgi GO:0042147 9.4 CLN5 VPS53
2 RNA phosphodiester bond hydrolysis, endonucleolytic GO:0090502 9.37 RNASEH2A RNASEH2B
3 lysosome organization GO:0007040 9.32 CLN6 PPT1
4 RNA catabolic process GO:0006401 9.26 RNASEH2A RNASEH2B
5 cellular macromolecule catabolic process GO:0044265 9.16 CLN6 PPT1
6 protein catabolic process GO:0030163 9.13 CLN5 CLN6 PPT1
7 lysosomal lumen acidification GO:0007042 8.8 CLN5 CLN6 PPT1

Molecular functions related to Cerebral Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA-DNA hybrid ribonuclease activity GO:0004523 8.62 RNASEH2A RNASEH2B

Sources for Cerebral Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....